Latest Healthcare News

nib holdings limited signals higher-than-expected non-recurring expenses in the first half of 2026, impacting statutory profit but leaving underlying performance steady.

Epsilon Healthcare Limited is poised to return to ASX trading on 19 December 2025 after satisfying the exchange's conditions for reinstatement.

Epsilon Healthcare Limited has unveiled a comprehensive pre-reinstatement disclosure, highlighting improved financial health and a strategic growth plan focused on operational stability and expansion.

Epsilon Healthcare has bolstered its working capital through a $2 million loan from its Managing Director and deferred director-related payments until 2027, signaling confidence amid liquidity management efforts.

Cleo Diagnostics has raised $5 million to support the U.S. commercial launch of its Pre-Surgical Ovarian Cancer Test and accelerate development of a mass screening test, signaling strong investor confidence in its technology.

Orthocell has reached a significant milestone with 100 units of its nerve repair product Remplir™ sold in the US, signaling accelerating adoption in a $1.6 billion market. The company’s strategic medical education and distributor network are driving momentum ahead of further hospital approvals.

Receivers and administrators have been appointed to 54 pharmacies within the Infinity Retail Pharmacy Group, catching Paragon Care off guard despite ongoing debt restructuring talks. The company pledges to support an orderly resolution to maximise creditor returns.

Memphasys Limited’s partner International Technical Legacy has placed an early order for 500 Felix™ cartridges ahead of anticipated CE Mark approval, signalling strong clinic demand and validating the company’s direct-selling strategy in the Middle East.

Aumake Limited has obtained a Hong Kong pharmaceutical wholesale licence, enabling it to launch up to five online over-the-counter medicine stores targeting Chinese consumers. This strategic move positions the company to tap into China’s rapidly expanding OTC market.

BlinkLab Limited has appointed its Co-Founder and CEO, Dr Henk-Jan Boele, as Managing Director to steer the company through its pivotal FDA 510(k) trial for its autism diagnostic technology. The move coincides with key board changes and signals a strategic shift as BlinkLab prepares for early commercialisation.

Actinogen Medical has finalized enrollment and begun treatment of all 246 participants in its XanaMIA Phase 2b/3 Alzheimer’s trial, with topline results expected in November 2026. The oral drug Xanamem targets brain cortisol to potentially slow disease progression.

TrivarX Limited has reported compelling clinical trial results demonstrating its single-lead ECG algorithm’s high sensitivity in detecting major depressive episodes among US veterans, marking a significant step in objective mental health screening.